Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 15 2 2019
medline: 26 11 2019
entrez: 15 2 2019
Statut: ppublish

Résumé

Background and Purpose- We report the relation of onset-to-treatment time and door-to-needle time with functional outcomes and mortality among patients with ischemic stroke with imaging-proven large vessel occlusion treated with intravenous alteplase. Methods- Individual patient-level data from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration were pooled from 7 trials that randomized patients to mechanical thrombectomy added to best medical therapy versus best medical therapy alone. Analysis was restricted to patients who received alteplase directly at the endovascular hospital. The primary outcome was disability defined on the modified Rankin Scale at 3 months. Results- Among 601 patients, mean age was 66.0 years (SD, 13.9), 50% were women, and median National Institutes of Health Stroke Scale score was 17. Onset-to-treatment time was median 125 minutes (interquartile range, 90-170). Door-to-treatment time was median 38 minutes (interquartile range, 26-55). Each 60-minute onset-to-treatment time delay was associated with greater disability at 90 days; the odds of functional independence (modified Rankin Scale, 0-2) at 90 days was 0.82 (95% CI, 0.66-1.03). With each 60-minute delay in door-to-needle time; the odds of functional independence was 0.55 (95% CI, 0.37-0.81) at 90 days. The absolute decline in the rate of excellent outcome (modified Rankin Scale, 0-1 at 90 days) was 20.3 per 1000 patients treated per 15-minute delay in door-to-needle time. The adjusted absolute risk difference for a door-to-needle time <30 minutes versus 30 to 60 minutes was 19.3% for independent outcome (number-needed-to-treat ≈5 to gain 1 additional good outcome). Symptomatic intracranial hemorrhage occurred in 3.4% of patients, without a significant time dependency: odds ratio, 0.74 (95% CI, 0.43-1.28). Conclusions- Faster intravenous thrombolysis delivery is associated with less disability at 3 months among patients with large vessel occlusion.

Identifiants

pubmed: 30760169
doi: 10.1161/STROKEAHA.118.021840
doi:

Substances chimiques

Plasminogen Activators EC 3.4.21.-
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-651

Subventions

Organisme : Department of Health
ID : HTA/14/08/47
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Auteurs

Mayank Goyal (M)

From the Department of Radiology (M.G.), University of Calgary, Alberta, Canada.

Mohammed Almekhlafi (M)

Department of Clinical Neurosciences (M.A.), University of Calgary, Alberta, Canada.

Diederik W Dippel (DW)

Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands (D.W.D.).

Bruce C V Campbell (BCV)

Department of Medicine and Neurology (B.C.V.C.), University of Melbourne, Australia.

Keith Muir (K)

Institute of Neuroscience and Psychology, University of Glasgow, United Kingdom (K.M.).

Andrew M Demchuk (AM)

Department of Clinical Neurosciences (A.M.D.), University of Calgary, Alberta, Canada.

Antoni Davalos (A)

Department of Neuroscience, University Autònoma de Barcelona, Spain (A.D.).

Francis Guillemin (F)

Department of Clinical Epidemiology, Neuroradiologie diagnostique et thérapeutique, Nancy, France (F.G.).

Tudor G Jovin (TG)

Department of Neurology, Stroke Institute, University of Pittsburgh, PA (T.G.J.).

Bijoy K Menon (BK)

Department of Clinical Neurosciences (B.K.M.), University of Calgary, Alberta, Canada.

Peter J Mitchell (PJ)

Department of Radiology (P.J.M.), University of Melbourne, Australia.

Scott Brown (S)

Neuroradiologie diagnostique et thérapeutique, Nancy, France (S.B.).
Altair Biostatistics, St. Louis Park, MN (S.B.).

Philip White (P)

Institute of Neuroscience, University of Newcastle, United Kingdom (P.W.).

Charles B L M Majoie (CBLM)

Department of Radiology, Amsterdam Medical Center, the Netherlands (C.B.L.M.M.).

Jeffrey L Saver (JL)

Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.).

Michael D Hill (MD)

Calgary Stroke Program, Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, Health Science Centre (M.D.H.), University of Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH